Hostname: page-component-6bf8c574d5-t27h7 Total loading time: 0 Render date: 2025-02-21T13:19:13.855Z Has data issue: false hasContentIssue false
  • English
  • Français

What We Have Learned About Sleep Disorders and Psychosis After Nearly Two Centuries of Parkinson's Disease

Published online by Cambridge University Press:  07 November 2014

Hubert H. Fernandez
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Summary and Conclusions
Information
CNS Spectrums , Volume 13 , Issue S4: Neuropsychiatric Aspects of Parkinson's Disease: Focus on Insomnia, Daytime Sleepiness, and Psychosis , March 2008 , pp. 34 - 35
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Disclosures: Dr. Fernandez is a consultant, paid speaker, or has performed clinical research for Allerga, Amarin, AstraZeneca, Aventis, Biogen Idee, Boehringer-lngelheim, Boston Life Sciences, Cephalon, Eisai, Elan, Forest, GlaxoSmithKline, Huntington Study Group, Ipsen, Kyowa, Merck KgaA, Merz, Michael J. Fox Foundation, MylanBertek, National Parkinson Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, Neurotrax, Novartis, Parkinson Study Group, Society of Progressive Supranuclear Palsy, Solstice, Solvay, Teva, United Biosource Corporation, The Cognition Group, Valeant, and Vernalis.